"Black Fungus" in the Indian Subcontinent: Prevention and Cure - Online CME Course
Recorded: June 23, 2021
On Wednesday, June 23rd, Mayo Clinic and guest experts discussed the probable causes of the COVID-19 associated rhino-orbital mucormycosis (“black fungus”) crisis in India, as well as therapeutic strategies for COVID-19 that can help to mitigate risks. In addition to medical and surgical treatment options, the role of monoclonal antibodies in high-risk patients will be addressed.
The views and perspectives shared in these resources are presented based on information available at the time of recording.
You are invited to watch the video by clicking on the above image.
To claim CME credit for this segment (1.50 hours / $00), follow these steps
- Click on the Register tab
- Register for the course (no fee, so no checkout process - just be sure you are logged in to your account profile.)
- Select the Start button, and then select Start Course button at the bottom of the screen.
- Complete the evaluation/assessment and claim credit.
- If you need additional assistance, contact usor call our toll-free number, 1-800-323-2688.
Healthcare workers of all specialties who are being impacted by COVID-19, including physicians, research scientists, physician assistants, nurse practitioners, nurses, and anyone with a particular interest in prevention, treatment, and patient care.
Upon completion of this activity, you will be able to:
- Explain probable causes of the COVID-19 associated rhino-orbital mucormycosis (“black fungus”) crisis in India
- Outline therapeutic strategies for COVID-19 that mitigate risk of mucormycosis
- Highlight the specific role of monoclonal antibodies in high-risk COVID-19 patients at risk of mucormycosis
- Discuss medical and surgical treatment algorithms for rhino orbital mucormycosis
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
This educational activity is supported in part by an
independent medical education grant from
Eli Lilly and Company
and is in accordance with ACCME guidelines.
Amit K. Ghosh, M.D., M.B.A.
|Devyani Lal, M.D.|
Professor of Otolaryngology, College of Medicine
Dean of Education, Mayo Clinic in Arizona
Chair, Division of Rhinology
Mayo Clinic in Arizona
|Arun Kumar Agarwal, D.Sc.|
Medical Advisor - Innovation, Education and
Apollo Hospitals Group
Patna, Bihar, India
Alok Thakar, M.S., F.R.C.S.
|H. R. Vikram, M.D.|
Professor of Medicine,
College of Medicine
Mayo Clinic in Arizona
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 1.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
The American Osteopathic Association designates this program for a maximum of 1.50 AOA Category 2-A credits.
Other Healthcare Professionals
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 AOA Category 2-A
- 1.50 Attendance